{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:36:11Z","timestamp":1778052971868,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Cancer patients are disproportionately affected by generalized anxiety and major depression. For many, current treatments for these conditions are ineffective. In this case report, we present a serendipitous case of anxiety and depression improvement following administration of the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 61-year old woman with a 20-year history of mild depression developed recurrent ovarian carcinoma and was placed on niraparib for maintenance chemotherapy. With the original onset of ovarian cancer, she experienced an episode of major depression that was resolved with sertraline. After recurrence of ovarian cancer, she experienced a recurrence of major depression and a new onset of generalized anxiety that failed to completely respond to multiple medications. After beginning niraparib therapy the patient noticed a rapid resolution of the symptoms of her anxiety and depression, an effect that was limited to 10\u201314\u2009days. Due to bone marrow suppression, the patient was taken off and restarted on niraparib several times. Each discontinuation of niraparib resulted in return of her depression and anxiety, while each recontinuation of niraparib resulted in an improvement in her mood and anxiety.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This case demonstrates rapid and temporary improvement of anxiety and depression following niraparib administration. There is ample preclinical data that PARP signaling may play a role in psychiatric illness. A small amount of indirect data from clinical trials also shows that niraparib may have psychiatric benefits. Further research on PARP inhibition and its potential psychoactive effects is sorely needed.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12888-020-02590-4","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T14:02:41Z","timestamp":1586959361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Benjamin E.","family":"Jewett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merry N.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libby A.","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Ordway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"2590_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological haematological and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160\u201374.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2590_CR2","doi-asserted-by":"publisher","first-page":"e0007618","DOI":"10.1136\/bmjopen-2015-007618","volume":"5","author":"S Watts","year":"2015","unstructured":"Watts S, Prescott P, Mason J, McLeod N, Lewith G. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2015;5(11):e0007618.","journal-title":"BMJ Open"},{"key":"2590_CR3","doi-asserted-by":"crossref","unstructured":"Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509\u201314.","DOI":"10.3892\/ol.2015.2944"},{"issue":"6","key":"2590_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449\u201359.","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"2590_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","volume":"84","author":"M De Vos","year":"2012","unstructured":"De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012 Jul;84(2):137\u201346.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2590_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMcibr1814680","volume":"380","author":"AL Olsen","year":"2019","unstructured":"Olsen AL, Feany MB. PARP inhibitors and Parkinson\u2019s disease. N Engl J Med. 2019;380(5):492\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"2590_CR7","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1007\/s12035-017-0646-8","volume":"55","author":"PL Wencel","year":"2018","unstructured":"Wencel PL, Lukiw WJ, Strosznajder JB, Strosznajder RP. Inhibition of poly (ADP-ribose) polymerase-1 enhances gene expression of selected sirtuins and app cleaving enzymes in amyloid beta cytotoxicity. Mol Neurobiol. 2018;55(6):4612\u201323.","journal-title":"Mol Neurobiol"},{"issue":"10","key":"2590_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/nm1097-1089","volume":"3","author":"MJL Eliasson","year":"1997","unstructured":"Eliasson MJL, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly (ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med. 1997;3(10):1089\u201395.","journal-title":"Nat Med"},{"issue":"12","key":"2590_CR9","first-page":"994","volume":"20","author":"GA Ordway","year":"2017","unstructured":"Ordway GA, Szebeni A, Hernandez LJ, Crawford JD, Szebeni K, Chandley MJ, et al. Antidepressant-like actions of inhibitors of poly (ADP-ribose) polymerase in rodent models. Int J Neuropsychopharmacol. 2017;20(12):994\u20131004.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"2590_CR10","first-page":"363","volume":"20","author":"A Szebeni","year":"2017","unstructured":"Szebeni A, Szebeni K, DiPeri TP, Johnson LA, Stockmeier CA, Crawford JD, et al. Elevated DNA oxidation and DNA repair enzyme expression in brain white matter in major depressive disorder. Int J Neuropsychopharmacol. 2017;20(5):363\u201373.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"2590_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1177\/0269881119874461","volume":"33","author":"M Ahmadimanesh","year":"2019","unstructured":"Ahmadimanesh M, Abbaszadegan MR, Morshedi Rad D, Moallem SA, Mohammadpour AH, Ghahremani MH, et al. Effects of selective serotonin reuptake inhibitors on DNA damage in patients with depression. J Psychopharmacol. 2019;33(11):1364\u201376.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"2590_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/brb3.239","volume":"4","author":"RI Mart\u00ednez-Zamudio","year":"2014","unstructured":"Mart\u00ednez-Zamudio RI, Ha HC. PARP1 enhances inflammatory cytokine expression by alteration of promoter chromatin structure in microglia. Brain Behav. 2014;4(4):552\u201365.","journal-title":"Brain Behav"},{"key":"2590_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","volume":"246","author":"JC Felger","year":"2013","unstructured":"Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199\u2013229.","journal-title":"Neuroscience."},{"issue":"4","key":"2590_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s002130050630","volume":"137","author":"S Lacosta","year":"1998","unstructured":"Lacosta S, Merali Z, Anisman H. Influence of interleukin-1\u03b2 on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice. Psychopharmacology. 1998;137(4):351\u201361.","journal-title":"Psychopharmacology."},{"issue":"1","key":"2590_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1021\/cn300186b","volume":"4","author":"NL Baganz","year":"2013","unstructured":"Baganz NL, Blakely RD. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci. 2013;4(1):48\u201363.","journal-title":"ACS Chem Neurosci"},{"issue":"25","key":"2590_CR16","doi-asserted-by":"publisher","first-page":"9685","DOI":"10.1073\/pnas.0600554103","volume":"103","author":"CC Alano","year":"2006","unstructured":"Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly (ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A. 2006;103(25):9685\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2590_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jad.2017.10.042","volume":"227","author":"JD Rosenblat","year":"2018","unstructured":"Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J Affect Disord. 2018;227:219\u201325.","journal-title":"J Affect Disord"},{"issue":"2","key":"2590_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1042\/BJ20111057","volume":"443","author":"E Toledano","year":"2012","unstructured":"Toledano E, Ogryzko V, Danchin A, Ladant D, Mechold U. 3\u2032-5\u2032 Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo. Biochem J. 2012;443(2):485\u201390.","journal-title":"Biochem J"},{"key":"2590_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pbb.2015.03.022","volume":"133","author":"CS Sriram","year":"2015","unstructured":"Sriram CS, Jangra A, Gurjar SS, Hussain MI, Borah P, Lahkar M, et al. Poly (ADP-ribose) polymerase-1 inhibitor, 3-aminobenzamide pretreatment ameliorates lipopolysaccharide-induced neurobehavioral and neurochemical anomalies in mice. Pharmacol Biochem Behav. 2015;133:83\u201391.","journal-title":"Pharmacol Biochem Behav"},{"key":"2590_CR20","unstructured":"Comparison of veliparib and whole brain radiation therapy (WBRT) versus placebo and WBRT in adults with brain metastases from non-small cell lung cancer - clinicaltrials.gov Identifier: NCT01657799. US National Library of Medicine; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01657799. Accessed Jan 2020."},{"key":"2590_CR21","unstructured":"A study evaluating efficacy of ABT-888 in combination with temozolomide in metastatic melanoma clinicaltrials.gov Identifier: NCT00804908. U.S. National Library of Medicine; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00804908. Accessed Jan 2020."},{"key":"2590_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fonc.2018.00670","volume":"8","author":"SK Gupta","year":"2019","unstructured":"Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, et al. PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: impact of blood-brain barrier and molecular heterogeneity. Front Oncol. 2019;8:670.","journal-title":"Front Oncol"},{"issue":"98","key":"2590_CR23","doi-asserted-by":"publisher","first-page":"37080","DOI":"10.18632\/oncotarget.26354","volume":"9","author":"K Sun","year":"2018","unstructured":"Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget. 2018;9(98):37080\u201396.","journal-title":"Oncotarget."},{"issue":"3","key":"2590_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/10401230591002002","volume":"17","author":"F L\u00f3pez-Mu\u00f1oz","year":"2005","unstructured":"L\u00f3pez-Mu\u00f1oz F, Alamo C, Cuenca E, Shen W, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113\u201335.","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"2590_CR25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.31887\/DCNS.2006.8.3\/tban","volume":"8","author":"TA Ban","year":"2006","unstructured":"Ban TA. The role of serendipity in drug discovery. Dialogues Clin Neurosci. 2006;8(3):335\u201344.","journal-title":"Dialogues Clin Neurosci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02590-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:37:21Z","timestamp":1618443441000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02590-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2590"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02590-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"4 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case study was performed in accordance with an approved East Tennessee State University Institutional Review Board protocol (IRB#: 0319.4e) that included informed consent of the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent to publish this case report was obtained from the patient. A copy of the written consent is available for review by the editor of <i>BMC Psychiatry<\/i>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BJE, MNM, LAL, ZC, and IM have no competing interests. Part of the salary of GAO is paid for by grants from the National Institutes of Health (MH114161-01A1; MH115384-01A1) and the American Foundation for Suicide Prevention (DIG-0-109-17), neither of which had any role in any part of this case study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}